Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$358.00K$358.00K+7.2% vs Q2 2021 Net Income-$12.79M-$12.79MN/M vs Q2 2021 EPS Diluted-$0.07-$0.07N/M vs Q2 2021 Operating Income-$12,799,500N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$11,500,100— Margins · derivedOperating margin-3575.3%−2589.1 pt vs Q2 2021
Net margin-3573.9%−2586.5 pt vs Q2 2021
ended Sep 30, 2021 · filed Nov 10, 2021 · 41 d after period end